Evidence map›Paper›PMID 41244623›Full record

ArticleAdvances in radiation oncology2025

Carbon Ion Versus Photon-based Stereotactic Ablative Radiation Therapy for Patients with Choroidal Melanoma.

Jina Kim, Masaru Wakatsuki, Shuri Aoki, Jong Won Park, Nao Kobayashi, Ki Chang Keum, Hirokazu Makishima, Christopher Seungkyu Lee, Hitoshi Ishikawa, Kyung Hwan Kim

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advances in radiation oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Jina KimDepartment of Radiation Oncology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea.
Masaru WakatsukiQST Hospital, National Institutes for Quantum Science and Technology, Chiba, Japan.
Shuri AokiQST Hospital, National Institutes for Quantum Science and Technology, Chiba, Japan.
Jong Won ParkDepartment of Radiation Oncology, Yonsei Cancer Center, Heavy Ion Therapy Research Institute, Yonsei University College of Medicine, Seoul, Republic of Korea.
Nao KobayashiQST Hospital, National Institutes for Quantum Science and Technology, Chiba, Japan.
Ki Chang KeumDepartment of Radiation Oncology, Yonsei Cancer Center, Heavy Ion Therapy Research Institute, Yonsei University College of Medicine, Seoul, Republic of Korea.
Hirokazu MakishimaQST Hospital, National Institutes for Quantum Science and Technology, Chiba, Japan.
Christopher Seungkyu LeeDepartment of Ophthalmology, The Institute of Vision Research, Yonsei University College of Medicine, Seoul, Republic of Korea.
Hitoshi IshikawaQST Hospital, National Institutes for Quantum Science and Technology, Chiba, Japan.
Kyung Hwan KimDepartment of Radiation Oncology, Yonsei Cancer Center, Heavy Ion Therapy Research Institute, Yonsei University College of Medicine, Seoul, Republic of Korea.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: To our knowledge, no study has compared the treatment outcomes of carbon ion radiation therapy (CIRT) and photon-based stereotactic ablative radiation therapy (SABR) in patients with choroidal melanoma. This study aimed to evaluate the treatment outcomes of patients with choroidal melanoma treated with CIRT or photon-based SABR. Methods and Materials: This study included 346 patients with localized choroidal melanoma who received CIRT or photon-based SABR between April 2001 and November 2021. Patients in the CIRT group received a median of 70 Gy delivered in a median dosage of 14 Gy per fraction, and patients in the SABR group received a median of 60 Gy delivered in a median dosage of 15 Gy per fraction. Propensity score matching (PSM) was performed to account for differences between the 2 groups. The main outcome was progression-free survival (PFS) in the PSM cohort, and secondary endpoints included overall survival, cumulative incidence of local and distant failures, and enucleation. Results: In all, 282 and 64 patients were included in the CIRT and SABR groups. After PSM, the 5-year PFS was significantly superior in the CIRT group to that in the SABR group (69.0% vs 56.5%, Conclusions: CIRT was found to be superior to SABR in patients with choroidal melanoma in terms of PFS, local control, and preservation of vision and eye.

Identifiers

PMID41244623
PMCPMC12615358

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.